| Project/Area Number |
23659187
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
CHIBA Hideki 福島県立医科大学, 医学部, 教授 (00295346)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TOMIKAWA Naoki 福島県立医科大学, 医学部, 講師 (80468587)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | タイト結合 / C 型肝炎ウィルス / 感染症 / 肝癌 / トうンスレーショナルリサーチ / 抗体医薬 / C型肝炎ウィルス / トランスレーショナルリサーチ / C型肝炎 |
|---|
| Research Abstract |
To prevent and treat Hepatitis C virus (HCV) infection, we generated a novel monoclonal antibody against human occludin. 15 clones of the purified antibodies showed no toxicity in the human hepatocellular carcinoma cell line Huh7.5.1. These antibodies did not inhibit HCV infection in Huh7.5.1 monolayer culture. However, when the fluorescent labeling antibody was applied to the lower chamber, the signal was detected along cell borders of Huh7.5.1 cells cultured in the upper chamber, suggesting that the novel antibody binds to occludin in living cells.
|
